Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from MicroPort NeuroTech Limited ( (HK:2172) ).
MicroPort NeuroScientific Corporation announced that its independently developed APOLLO Dream Rapamycin Target Eluting Stent System has received Breakthrough Device Designation from the U.S. Food and Drug Administration, the first balloon-expandable, rapid exchange drug-eluting stent in the neuro-interventional field to gain this status. Designed for patients with symptomatic intracranial arterial stenosis who do not respond to best medical therapy, the stent combines targeted rapamycin delivery, optimized mechanical support and biodegradable coating to improve cerebral blood flow and reduce restenosis and potential long-term thrombosis risk.
The FDA designation is expected to speed clinical development and regulatory review, support the device in addressing an unmet global need in intracranial atherosclerotic stenosis treatment and reinforce the Group’s globalization strategy by facilitating entry into overseas markets. The company plans to push ahead with global clinical studies and registrations for APOLLO Dream to broaden its international influence in neurovascular interventional therapies, while cautioning that there is no assurance the device will ultimately be successfully commercialized.
The most recent analyst rating on (HK:2172) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on MicroPort NeuroTech Limited stock, see the HK:2172 Stock Forecast page.
More about MicroPort NeuroTech Limited
MicroPort NeuroScientific Corporation is a Cayman Islands-incorporated medical device company focused on neurovascular interventional therapies. The Group develops innovative stent and related systems targeting intracranial arterial diseases, with a strategic emphasis on expanding its presence in key international markets, particularly in advanced neuro-interventional treatment segments.
Average Trading Volume: 6,839,156
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.61B
Learn more about 2172 stock on TipRanks’ Stock Analysis page.